CONTACT NEUROPTIKA

1770 Massachusetts Avenue, Suite 163 Cambridge, MA  02140

United States

Copyright, Neuroptika 2019. All rights reserved.  Terms of site use  |  Privacy Policy

ABOUT NEUROPTIKA

Neuroptika is a clinical stage biotechnology company formed in November 2018 as a spin out of Senju Pharmaceutical Co., Ltd, a privately held pharmaceutical company based in Osaka, Japan. Neuroptika is developing NRO-1, a novel therapeutic that protects and regenerates corneal nerves. NRO-1 has generated compelling data demonstrating accelerated nerve regeneration which led to the recovery of functional nerves and corneal sensitivity in animal studies. 

 

A successful Phase 1 SAD/MAD clinical study is complete and we plan to initiate a Phase 2 clinical study for dry eye disease in the second half of 2019.  While most dry eye treatments are focused on treating signs and symptoms, NRO-1 has the potential to become the first disease modifying regenerative treatment. NRO-1’s benefit is also being studied in other indications, including post-LASIK care, glaucoma and Leber's hereditary optic neuropathy.  Our mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases.  

 
 

NEUROPTIKA TEAM

 

BOARD OF DIRECTORS

 

BACK TO TOP